clinical trial · NCT04773587
Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis
Atopic Dermatitis EczemaRoflumilast Cream 0.15%Vehicle Cream
brief summary
This is a parallel group, double blind, vehicle-controlled study to assess the safety and efficacy of roflumilast (ARQ-151) cream vs vehicle applied once daily (qd) for 4 weeks by participants with atopic dermatitis (eczema).
started
Jan 27, 2021
primary completion
Aug 30, 2022
completion
Aug 30, 2022
last updated
Oct 9, 2024
official title
A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.15% Administered QD in Subjects With Atopic Dermatitis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol